Uniqure Ord Shs (NQ: QURE )

50.47 USD -0.20 (-0.40%)

Streaming Delayed Price Updated: 12:44 PM EST, Dec 3, 2020 Add to My Watchlist

Price and Volume

Volume	209,948
Open	50.96
Bid (Size)	50.48 (2)
Ask (Size)	50.57 (2)
Prev. Close	50.67
Today's Range	50.08 - 52.19
52wk Range	34.38 - 76.69
Shares Outstanding	31,683,988
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

uniQure to Participate in Multiple Upcoming Industry Conferences in December

December 02, 2020

uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting

November 30, 2020

Performance

YTD	-28.17%	-28.17%
1 Month	+23.48%	+23.48%
3 Month	+27.03%	+27.03%
6 Month	-19.62%	-19.62%
1 Year	-21.05%	-21.05%

More News

uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

November 19, 2020

uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting

November 04, 2020

uniQure to Participate in Multiple Upcoming Industry Conferences in November

November 04, 2020

uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress

October 27, 2020

uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

October 13, 2020

uniQure to Participate in Multiple Upcoming Industry Conferences in October

September 30, 2020

uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

September 25, 2020

uniQure to Participate in Multiple Upcoming Industry Conferences in September

September 03, 2020

UniQure Rallies On Positive Late-Stage Data For Hemophilia B Gene Therapy

November 19, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.